Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 12, 2019
Grant Date -
Dec 17, 2015
app pub date -
Feb 14, 2014
filing date -
Feb 15, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17-substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use as, for example, modulators for GABA type-A receptors. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully